Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Frequency Change of CR Oxycodone for Refractory Cancer Pain
NCT03639415Phase 4Withdrawn
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of oxycodone in cancer pain, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: The effective rate of treatment at 2 years. Planned start Oct 2018; status: withdrawn.
02
Drugs
oxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT03639415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639415.